Histological classification of ovarian cancer

Kaku, Tsunehisa; Ogawa, Shinji; Kawano, Yoshiaki; Ohishi, Yoshihiro; Kobayashi, Hiroaki; Hirakawa, Tsubasa; Nakano, Hitoo

doi:10.1007/s007950300002

Cited by 196 publications

(165 citation statements)

References 32 publications

Supporting

Mentioning

155

Contrasting

Unclassified

Order By: Relevance

“…Kallikreins 6 and 13 are expressed in normal epithelium (Petraki et al, 2001(Petraki et al, , 2003, including the OSE as we have shown here. Ovarian cancer is thought to arise from either OSE or OSE cells bordering inclusion cysts (Kaku et al, 2003), therefore it is expected that ovarian cancer cells would express a basal level of kallikrein expression. Given the semi-quantitative nature of immunohistochemistry and the fact that KLKs are secreted proteins, to see a significant difference in the cellular levels between normal OSE and ovarian cancer would require not only changes in KLK protein production, but also a significant change in the rate of kallikrein exocytosis.…”

Section: Discussionmentioning

confidence: 99%

KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma

et al. 2009

View full text Add to dashboard Cite

BACKGROUND: The human kallikrein-related peptidase family consists of 15 genes. Twelve of these genes are overexpressed in ovarian cancer and may represent potential markers for diagnosis, prognosis, and/or response to treatment. The aim of this study was to determine the prognostic significance of kallikrein-related peptidase 6 (KLK6) and kallikrein-related peptidase 13 (KLK13) in epithelial ovarian cancer by quantifying gene expression levels with tumour pathology and patient survival data. METHODS: Total RNA was isolated from 106 patients diagnosed with primary ovarian cancer, as well as 8 normal ovary controls. Samples were analysed by quantitative real-time PCR for KLK6 and KLK13 expression. Correlation between kallikrein gene expression and clinical characteristics was evaluated with the w 2 -test. Survival analysis was performed using Kaplan -Meier and Cox proportional hazards regression models. RESULTS: Expression levels of both KLK6 and KLK13 mRNA were significantly increased in invasive cancers relative to normal ovaries (P ¼ 0.002 and 0.039 respectively). High KLK6 and KLK13 expression was an indicator of poor prognosis, with patients having a shorter recurrence-free survival (P ¼ 0.002 and 0.027 respectively). High KLK6 expression was also significantly associated with lower overall survival (P ¼ 0.011). When subjected to multivariate analysis, patients with either high KLK6 or KLK13 were 3-and 2.2-fold, respectively, more likely to have a recurrence than patients with low kallikrein expression. CONCLUSION: These data show increased mRNA expression of KLK6 and KLK13 in ovarian cancer compared to normal ovarian tissues. High KLK6 or KLK13 expression in primary ovarian tumours can significantly predict prognosis in terms of recurrence-free survival and overall survival. In all, this study shows KLK6 and KLK13 as potential biomarkers and may be therapeutic targets for treatment of ovarian cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma

et al. 2009

View full text Add to dashboard Cite

show abstract

“…EOCs are commonly classified according to histopathological appearance as clear cell, endometrioid, mucinous or serous; amongst these, serous epithelial tumours are the most commonly diagnosed tumour type . However, wide varieties of less common ovarian neoplasms exist and can include mixed, undifferentiated or Brenner-type tumours (Kaku et al 2003, Arnogiannaki et al 2011. While traditionally subgrouped according to FIGO stage and grade, a growing body of evidence now suggests that low-and high-grade tumours have different aetiologies arising from unrelated, underlying molecular pathologies (Gilks et al 2008.…”

Section: Epithelial Ovarian Cancermentioning

confidence: 99%

The emerging role of CXC chemokines in epithelial ovarian cancer

et al. 2012

View full text Add to dashboard Cite

In recent years, chemokines have generated intense investigations due to their involvement in both physiological and pathological processes of inflammation, particularly in ovarian biology. The physiological process of ovulation in the normal ovary involves various chemokines that mediate the healing of the ruptured endometrium. It is now being reported that many of these chemokines are also associated with the cancer of the ovary. Chronic inflammation underlies the progression of ovarian cancer; therefore, it raises the possibility that chemokines are involved in the inflammatory process and mediate immune responses that may favour or inhibit tumour progression. Ovarian cancer is a gynaecological cancer responsible for highest rate of mortality in women. Although there have been several investigations and advances in surgery and chemotherapy, the survival rate for this disease remains low. This is mainly because of a lack of specific symptoms and biomarkers for detection. In this review, we have discussed the emerging role of the CXC chemokines in epithelial ovarian cancer (EOC). The CXC group of chemokines is gaining importance in the field of ovarian cancer for being angiostatic and angiogenic in function. While there have been several studies on the angiogenesis function, emerging research shows that ELR K CXC chemokines, CXCL9 and CXCL10, are angiostatic. Importantly, the angiostatic chemokines can inhibit the progression of EOC. Given that there are currently no biomarkers or specific therapeutic targets for the disease, these chemokines are emerging as promising targets for therapy.

show abstract

“…Chemotherapy resistance is a major cause of metastasis and recurrence. EOC accounts for 85-90% of clinical ovarian malignancies, and SOC is the main type of EOC (45). At present, excision repair cross-complementing rodent repair deficiency, complementation group 1 (ERCC1) is a key topic of studies attempting to predict chemotherapy resistance in ovarian cancer (46,47).…”

Section: Discussionmentioning

confidence: 99%

Overexpression of S100A14 in human serous ovarian carcinoma

et al. 2015

View full text Add to dashboard Cite

Abstract. S100 calcium binding protein A14 (S100A14) is a member of the S100 protein family that plays an important role in the progression of several types of cancer. In the present study, the expression and clinical effect of S100A14 was evaluated in serous ovarian carcinoma (SOC). SOC tissue specimens and a panel of normal ovarian and fallopian tubal tissue specimens were obtained between November 2008 and August 2012 from the Affiliated Hospital of Qingdao University. Immunohistochemistry (IHC) was used to detect the expression of S100A14 in the SOC and normal control tissues. In addition, ELISA was performed to assess S100A14 expression in a subset of serum samples. The association between the expression of S100A14 in SOC and the corresponding clinical and pathological data was analyzed. The IHC results revealed that S100A14 was mainly located in the cytoplasm of the majority of SOC cells, and the expression levels of S100A14 in the tumor tissues were significantly increased compared with the levels identified in normal ovarian specimens (P<0.001). Consistently, the serum levels of S100A14 in patients with SOC were also increased compared with the levels in healthy individuals (P<0.001). S100A14 expression was similar in the epithelium of SOC lesions and the fallopian tube, which supported the dualistic model for ovarian serous carcinogenesis. Additional analysis of the expression of S100A14 and corresponding clinical and pathological data revealed the correlation between the elevated expression of S100A14 and resistance to platinum-based chemotherapy. However, the protein level of S100A14 was not associated with the pathological stage, differentiation or metastasis of SOC. Overall, the present results demonstrate that S100A14 is likely to be involved in the resistance of SOC to platinum-based chemotherapy.

show abstract

Histological classification of ovarian cancer

Cited by 196 publications

References 32 publications

KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma

KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma

The emerging role of CXC chemokines in epithelial ovarian cancer

Overexpression of S100A14 in human serous ovarian carcinoma

Contact Info

Product

Resources

About